Cologne, August 1, 2025 — Ningaloo Biosystems has released new data demonstrating the effectiveness of its optogenetic platform in accelerating the development of production cell lines through tunable gene expression. The study, detailed in a recently published white paper, highlights how light-controlled expression systems can drastically reduce time-intensive screening traditionally required to identify optimal genetic configurations in host cells.
By enabling precise, real-time modulation of gene expression levels, the platform supports faster and more flexible optimization of bioproduction yields and quality. Importantly, the approach allows rapid data generation during transient screening, which can then inform stable cell line engineering using benchmarked constitutive promoters. Moreover, the optogenetic system can be directly applied in stable production settings, offering a versatile solution across the development lifecycle.
This advancement has the potential to significantly shorten timelines from DNA design to first-in-human clinical material, while also streamlining later-stage manufacturing processes.
Download the whitepaper here: Speed up Your Cell Line Development
About Ningaloo
Ningaloo Biosystems is pioneering advancements in biopharmaceutical production by engineering host cells for real-time process control through optogenetics. This approach enables cybergenetic bioprocessing to achieve unprecedented efficiency in manufacturing complex proteins and gene therapeutics, ultimately reducing costs and expanding access to cutting-edge treatments.